Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TEVA, APGE, ESTA, CBAY, IMVT, and represent 29.75% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: APGE (+$22M), TEVA (+$15M), CRNX (+$13M), ALKS (+$8.4M), ESTA (+$8.2M), XENE (+$8.2M), ARKG (+$7.0M), KRYS (+$6.7M), IMVT (+$6.5M), ACLX (+$6.2M).
- Started 27 new stock positions in TERN, TVTX, EYPT, CRNX, Seagen, MLTX, DVAX, MRSN, ARKG, MRTX.
- Reduced shares in these 10 stocks: Chinook Therapeutics (-$12M), , BBIO (-$10M), MDGL (-$8.9M), FGEN (-$6.2M), Esperion Therapeutics Inc Ne, VTYX, VRDN, Reata Pharmaceuticals Inc Cl A, Aeglea Biotherapeutics.
- Sold out of its positions in AADI, Aeglea Biotherapeutics, ALPN, AXSM, BIIB, CABA, Chinook Therapeutics, Esperion Therapeutics Inc Ne, FGEN, Intrexon Corp note 3.500% 7/0. Jasper Therapeutics, MLYS, Reata Pharmaceuticals Inc Cl A, VTYX, VINC, VIR, VRDN.
- Affinity Asset Advisors was a net buyer of stock by $96M.
- Affinity Asset Advisors has $356M in assets under management (AUM), dropping by 24.17%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 74 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 8.9 | $32M | +93% | 3.1M | 10.20 |
|
Apogee Therapeutics (APGE) | 6.3 | $22M | NEW | 1.0M | 21.30 |
|
Establishment Labs Holdings Ord (ESTA) | 5.2 | $19M | +79% | 379k | 49.07 |
|
Cymabay Therapeutics (CBAY) | 4.7 | $17M | +7% | 1.1M | 14.91 |
|
Immunovant (IMVT) | 4.6 | $16M | +64% | 428k | 38.39 |
|
Bridgebio Pharma Note 2.500% 3/1 (Principal) | 4.6 | $16M | +41% | 17M | 0.97 |
|
Cerevel Therapeutics Hldng I (CERE) | 4.2 | $15M | +24% | 685k | 21.83 |
|
Arcellx Common Stock (ACLX) | 4.0 | $14M | +76% | 400k | 35.88 |
|
Crinetics Pharmaceuticals In (CRNX) | 3.8 | $13M | NEW | 450k | 29.74 |
|
Madrigal Pharmaceuticals (MDGL) | 3.5 | $12M | -41% | 85k | 146.04 |
|
Xenon Pharmaceuticals (XENE) | 2.9 | $10M | +397% | 300k | 34.16 |
|
Alkermes SHS Call Option (ALKS) | 2.4 | $8.4M | NEW | 300k | 28.01 |
|
Kura Oncology (KURA) | 2.2 | $7.8M | -5% | 857k | 9.12 |
|
Astria Therapeutics (ATXS) | 2.1 | $7.5M | +53% | 1.0M | 7.46 |
|
Morphic Hldg (MORF) | 2.1 | $7.3M | +58% | 320k | 22.91 |
|
Viking Therapeutics Put Option (VKTX) | 2.0 | $7.0M | -2% | 633k | 11.07 |
|
Ark Etf Tr Genomic Rev Etf Put Option (ARKG) | 2.0 | $7.0M | NEW | 250k | 27.86 |
|
Cytokinetics Com New (CYTK) | 1.9 | $6.8M | +84% | 230k | 29.46 |
|
Krystal Biotech (KRYS) | 1.9 | $6.7M | NEW | 58k | 116.00 |
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.9 | $6.6M | +13% | 1.0M | 6.47 |
|
Apellis Pharmaceuticals Put Option (APLS) | 1.8 | $6.5M | +1600% | 170k | 38.04 |
|
Verona Pharma Sponsored Ads (VRNA) | 1.7 | $6.0M | -17% | 368k | 16.30 |
|
Inozyme Pharma (INZY) | 1.6 | $5.8M | +83% | 1.4M | 4.20 |
|
Autolus Therapeutics Spon Ads (AUTL) | 1.3 | $4.6M | +25% | 2.0M | 2.33 |
|
Savara (SVRA) | 1.2 | $4.3M | NEW | 1.2M | 3.78 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 1.2 | $4.3M | -19% | 46k | 93.64 |
|
Celldex Therapeutics Com New (CLDX) | 1.2 | $4.1M | +72% | 150k | 27.52 |
|
Astrazeneca Sponsored Adr (AZN) | 1.1 | $4.1M | 60k | 67.72 |
|
|
Tango Therapeutics (TNGX) | 1.1 | $3.9M | NEW | 350k | 11.26 |
|
Prothena Corp SHS (PRTA) | 1.1 | $3.8M | -20% | 79k | 48.25 |
|
Mersana Therapeutics (MRSN) | 1.0 | $3.6M | NEW | 2.9M | 1.27 |
|
Aeglea Biotherapeutics Com New (SYRE) | 0.8 | $3.0M | NEW | 242k | 12.25 |
|
Dynavax Technologies Corp Com New (DVAX) | 0.8 | $3.0M | NEW | 200k | 14.77 |
|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.8 | $2.9M | NEW | 50k | 57.00 |
|
Kalvista Pharmaceuticals (KALV) | 0.8 | $2.7M | +56% | 278k | 9.63 |
|
Mirati Therapeutics (MRTX) | 0.7 | $2.6M | NEW | 60k | 43.56 |
|
Immatics SHS (IMTX) | 0.7 | $2.3M | -33% | 200k | 11.58 |
|
Nuvalent Inc-a (NUVL) | 0.6 | $2.3M | NEW | 50k | 45.97 |
|
Seagen | 0.6 | $2.1M | NEW | 10k | 212.15 |
|
Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.6 | $2.1M | NEW | 30k | 69.48 |
|
Nurix Therapeutics (NRIX) | 0.6 | $2.0M | +150% | 250k | 7.86 |
|
Aclaris Therapeutics Put Option (ACRS) | 0.5 | $1.8M | NEW | 260k | 6.85 |
|
Roivant Sciences SHS (ROIV) | 0.5 | $1.8M | NEW | 150k | 11.68 |
|
Terns Pharmaceuticals (TERN) | 0.5 | $1.6M | NEW | 325k | 5.03 |
|
Vaxcyte (PCVX) | 0.4 | $1.3M | +79% | 25k | 50.98 |
|
Inspire Med Sys (INSP) | 0.4 | $1.2M | NEW | 6.3k | 198.44 |
|
Eyepoint Pharmaceuticals Com New Put Option (EYPT) | 0.3 | $1.2M | NEW | 155k | 7.99 |
|
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.3 | $1.2M | +25% | 125k | 9.25 |
|
Talaris Therapeutics | 0.3 | $1.1M | +100% | 400k | 2.81 |
|
Theseus Pharmaceuticals (THRX) | 0.3 | $1.1M | +66% | 401k | 2.69 |
|
Milestone Pharmaceuticals (MIST) | 0.3 | $1.0M | +11% | 335k | 3.10 |
|
Lianbio Sponsored Ads (LIAN) | 0.3 | $1.0M | -16% | 672k | 1.49 |
|
Adc Therapeutics Sa SHS (ADCT) | 0.3 | $987k | +83% | 1.1M | 0.90 |
|
Inflarx Nv (IFRX) | 0.3 | $969k | +35% | 325k | 2.98 |
|
Springworks Therapeutics (SWTX) | 0.3 | $961k | -68% | 42k | 23.12 |
|
Mirum Pharmaceuticals (MIRM) | 0.3 | $948k | 30k | 31.60 |
|
|
Travere Therapeutics (TVTX) | 0.3 | $894k | NEW | 100k | 8.94 |
|
Insulet Corporation (PODD) | 0.2 | $798k | NEW | 5.0k | 159.49 |
|
Bridgebio Pharma (BBIO) | 0.2 | $791k | -92% | 30k | 26.37 |
|
Biohaven (BHVN) | 0.2 | $784k | NEW | 30k | 26.01 |
|
Avrobio Ord (AVRO) | 0.2 | $770k | NEW | 500k | 1.54 |
|
Immatics *w Exp 07/01/202 (IMTXW) | 0.2 | $663k | 187k | 3.54 |
|
|
89bio Call Option (ETNB) | 0.2 | $576k | NEW | 37k | 15.44 |
|
Puma Biotechnology (PBYI) | 0.1 | $532k | 202k | 2.63 |
|
|
Promis Neurosciences Com New (PMN) | 0.1 | $527k | NEW | 266k | 1.98 |
|
Context Therapeutics (CNTX) | 0.1 | $497k | +22% | 329k | 1.51 |
|
Mesoblast Spons Adr Put Option (MESO) | 0.1 | $492k | NEW | 400k | 1.23 |
|
Nuvation Bio Com Cl A (NUVB) | 0.1 | $335k | 250k | 1.34 |
|
|
Bioatla (BCAB) | 0.1 | $306k | -44% | 180k | 1.70 |
|
Aldeyra Therapeutics (ALDX) | 0.1 | $296k | -70% | 44k | 6.68 |
|
Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $260k | +270% | 137k | 1.90 |
|
Nls Pharmaceutics SHS (NLSP) | 0.0 | $140k | -49% | 201k | 0.70 |
|
Aravive (ARAV) | 0.0 | $46k | -61% | 347k | 0.13 |
|
Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $7.5k | 75k | 0.10 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023
- Affinity Asset Advisors 2022 Q3 filed Nov. 14, 2022
- Affinity Asset Advisors 2022 Q2 filed Aug. 12, 2022
- Affinity Asset Advisors 2022 Q1 filed May 13, 2022
- Affinity Asset Advisors 2021 Q4 filed Feb. 11, 2022
- Affinity Asset Advisors 2021 Q3 filed Nov. 12, 2021
- Affinity Asset Advisors 2021 Q2 filed Aug. 13, 2021
- Affinity Asset Advisors 2021 Q1 filed May 14, 2021
- Affinity Asset Advisors 2020 Q4 filed Feb. 12, 2021